Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance.
Pathophysiology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
23 Jul 2021
23 Jul 2021
Historique:
received:
19
01
2021
revised:
01
06
2021
accepted:
22
06
2021
pubmed:
1
7
2021
medline:
1
7
2021
entrez:
30
6
2021
Statut:
ppublish
Résumé
Patients with COVID-19 can experience symptoms and complications after viral clearance. It is important to identify clinical features of patients who are likely to experience these prolonged effects. We conducted a retrospective study to compare longitudinal laboratory test measurements (hemoglobin, hematocrit, estimated glomerular filtration rate, serum creatinine, and blood urea nitrogen) in patients rehospitalized after PCR-confirmed SARS-CoV-2 clearance (n = 104) versus patients not rehospitalized after viral clearance (n = 278). Rehospitalized patients had lower median hemoglobin levels in the year prior to COVID-19 diagnosis (Cohen's D = -0.50; p = 1.2 × 10
Identifiants
pubmed: 34189429
doi: 10.1016/j.isci.2021.102780
pii: S2589-0042(21)00748-3
pmc: PMC8225287
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102780Informations de copyright
© 2021.
Déclaration de conflit d'intérêts
P.J.L., E.R., A.J.V., G.B., R.M., and V.S. are employees of nference and have financial interests in the company. J.C.O. receives personal fees from Elsevier and 10.13039/100016444Bates College, and receives small grants from nference, Inc, outside the submitted work. A.D.B. is a consultant for Abbvie, is on scientific advisory boards for nference and Zentalis, and is founder and President of Splissen therapeutics. J.C.O., W.M., J.H., and A.D.B. are employees of the Mayo Clinic. The Mayo Clinic may stand to gain financially from the successful outcome of the research.
Références
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Cell Rep. 2020 Sep 22;32(12):108175
pubmed: 32946807
Nat Methods. 2020 Mar;17(3):352
pubmed: 32094914
BMC Infect Dis. 2021 Feb 10;21(1):170
pubmed: 33568084
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Crit Care Res Pract. 2013;2013:479730
pubmed: 23573420
JAMA. 2020 Nov 3;324(17):1723-1724
pubmed: 33031513
EClinicalMedicine. 2021 Apr;34:100793
pubmed: 33778434
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Clin Biochem Rev. 2016 May;37(2):85-98
pubmed: 28303073
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759
pubmed: 32663409
Intensive Care Med. 2006 Aug;32(8):1206-13
pubmed: 16741693
Nat Rev Nephrol. 2020 Dec;16(12):747-764
pubmed: 33060844
Clin Kidney J. 2019 Nov 18;13(2):133-141
pubmed: 32296515
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
Elife. 2020 Jul 07;9:
pubmed: 32633720
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Elife. 2020 May 28;9:
pubmed: 32463365
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Am J Emerg Med. 2021 Mar 29;48:140-147
pubmed: 33895645
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Intensive Care. 2017 Sep 16;5:57
pubmed: 28932401
Lancet Infect Dis. 2020 Oct;20(10):1115-1117
pubmed: 32888409
JAMA Netw Open. 2020 Sep 1;3(9):e2017843
pubmed: 32970158
Ann Intern Med. 2019 Jan 15;170(2):81-89
pubmed: 30557414
Transfus Apher Sci. 2020 Dec;59(6):102926
pubmed: 32893135
NPJ Vaccines. 2020 Sep 28;5:91
pubmed: 33083026
Elife. 2020 May 26;9:
pubmed: 32452762